Reliance Industries' consolidated net profit rose 17.93% to Rs 9549 crore on 54.11% rise in total income to Rs 144574 crore in Q2 September 2018 over Q2 September 2017. The result was announced after market hours on Wednesday, 17 October 2018.

State Bank of India said that the meeting of the board of directors of the bank is scheduled on 22 October 2018, inter alia, to consider and approve to pass enabling resolution for raising of equity capital from the market by way of FPO/ QlP/ preferential allotment/ rights issue/ any other mode or a combination of these. The announcement was made after market hours on Wednesday, 17 October 2018.

ACC reported 15.21% rise in consolidated net profit to Rs 209.14 crore on 10.34% rise in total income to Rs 3468.37 crore in Q3 September 2018 over Q3 September 2017. The result was announced after market hours on Wednesday, 17 October 2018.

Havells India's net profit rose 4.44% to Rs 178.62 crore on 23.21% rise in total income to Rs 2225.31 crore in Q2 September 2018 over Q2 September 2017. The result was announced after market hours on Wednesday, 17 October 2018.

Zydus Cadila received the tentative approval from the USFDA to market Colchicine Tablets USP (US RLD —ColcyrsTM), 0.6 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to prevent or treat attacks of gout (also called gouty arthritis). This medication is also used to prevent attacks of pain in the abdomen, chest or joints caused by a genetic autoinflammatory disease (called as familial Mediterranean fever).